|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
McWhinney SR, Goldberg RM and McLeod HL:
Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 8:10–16.
2009. View Article : Google Scholar
|
|
3
|
Gerber DE and Choy H: Cetuximab in
combination therapy: from bench to clinic. Cancer Metastasis Rev.
29:171–180. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rodriguez J, Zarate R, Bandres E, Viudez
A, Chopitea A, García-Foncillas J and Gil-Bazo I: Combining
chemotherapy and targeted therapies in metastatic colorectal
cancer. World J Gastroenterol. 28:5867–5876. 2007. View Article : Google Scholar
|
|
5
|
Wadlow RC and Ryan DP: The role of
targeted agents in preoperative chemoradiation for rectal cancer.
Cancer. 116:3537–3548. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Johnson SM, Gulhati P, Rampy BA, Han Y,
Rychahou PG, Doan HQ, Weiss HL and Evers BM: Novel expression
patterns of PI3K/Akt/mTOR signaling pathway components in
colorectal cancer. J Am Coll Surg. 210:767–776. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Silvestris N, Tommasi S, Petriella D,
Santini D, Fistola E, Russo A, Numico G, Tonini G, Maiello E and
Colucci G: The dark side of the moon: the PI3K/PTEN/AKT pathway in
colo-rectal carcinoma. Oncology. 77(Suppl 1): 69–74. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Merimsky O, Gorzalczany Y and
Sagi-Eisenberg R: Molecular impacts of rapamycin-based drug
combinations: combining rapamycin with gemcitabine or imatinib
mesylate (Gleevec) in a human leiomyosarcoma model. Int J Oncol.
31:225–232. 2007.
|
|
9
|
Pencreach E, Guérin E, Nicolet C,
Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP and Guenot
D: Marked activity of irinotecan and rapamycin combination toward
colon cancer cells in vivo and in vitro is mediated through
cooperative modulation of the mammalian target of
rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res.
15:1297–1307. 2009. View Article : Google Scholar
|
|
10
|
Perotti A, Locatelli A, Sessa C, Hess D,
Viganò L, Capri G, Maur M, Cerny T, Cresta S, Rojo F, Albanell J,
Marsoni S, Corradino I, Berk L, Rivera VM, Haluska F and Gianni L:
Phase IB study of the mTOR inhibitor ridaforolimus with
capecitabine. J Clin Oncol. 28:4554–4561. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Houghton PJ, Morton CL, Gorlick R, Lock
RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu
J, Wozniak AW, Billups CA, Rubinstein L and Smith MA: Stage 2
combination testing of rapamycin with cytotoxic agents by the
Pediatric Preclinical Testing Program. Mol Cancer Ther. 9:101–112.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Eisenberg-Lerner A, Bialik S, Simon HU and
Kimchi A: Life and death partners: apoptosis, autophagy and the
cross-talk between them. Cell Death Differ. 16:966–975. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Raje N, Kumar S, Hideshima T, Ishitsuka K,
Chauhan D, Mitsiades C, Podar K, Le Gouill S, Richardson P, Munshi
NC, Stirling DI, Antin JH and Anderson KC: Combination of the mTOR
inhibitor rapamycin and CC-5013 has synergistic activity in
multiple myeloma. Blood. 104:4188–4193. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gu J, Yamamoto H, Lu X, Ngan CY, Tsujino
T, Konishi K, Takemasa I, Ikeda M, Nagata H, Hashimoto S, Matsuzaki
T, Sekimoto M, Takagi A and Monden M: Low-dose oxaliplatin enhances
the antitumor efficacy of paclitaxel in human gastric cancer cell
lines. Digestion. 74:19–27. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paglin S, Hollister T, Delohery T, Hackett
N, McMahill M, Sphicas E, Domingo D and Yahalom J: A novel response
of cancer cells to radiation involves autophagy and formation of
acidic vesicles. Cancer Res. 61:439–444. 2001.PubMed/NCBI
|
|
16
|
Park SB, Goldstein D, Lin CS, Krishnan AV,
Friedlander ML and Kiernan MC: Acute abnormalities of sensory nerve
function associated with oxaliplatin-induced neurotoxicity. J Clin
Oncol. 27:1243–1249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagata Y, Takahashi A, Ohnishi K, Ota I,
Ohnishi T, Tojo T and Taniguchi S: Effect of rapamycin, an mTOR
inhibitor, on radiation sensitivity of lung cancer cells having
different p53 gene status. Int J Oncol. 37:1001–1010. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shigematsu H, Yoshida K, Sanada Y, Osada
S, Takahashi T, Wada Y, Konishi K, Okada M and Fukushima M:
Rapamycin enhances chemotherapy-induced cytotoxicity by inhibiting
the expressions of TS and ERK in gastric cancer cells. Int J
Cancer. 126:2716–2725. 2010.PubMed/NCBI
|
|
19
|
Fung AS, Wu L and Tannock IF: Concurrent
and sequential administration of chemotherapy and the Mammalian
target of rapamycin inhibitor temsirolimus in human cancer cells
and xenografts. Clin Cancer Res. 15:5389–5395. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Francis LK, Alsayed Y, Leleu X, Jia X,
Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA,
Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC and
Ghobrial IM: Combination mammalian target of rapamycin inhibitor
rapamycin and HSP90 inhibitor
17-allylamino-17-demethoxygeldanamycin has synergistic activity in
multiple myeloma. Clin Cancer Res. 12:6826–6835. 2006. View Article : Google Scholar
|
|
21
|
Mondesire WH, Jian W, Zhang H, Ensor J,
Hung MC, Mills GB and Meric-Bernstam F: Targeting mammalian target
of rapamycin synergistically enhances chemotherapy induced
cytotoxicity in breast cancer cells. Clin Cancer Res. 10:7031–7042.
2004. View Article : Google Scholar
|
|
22
|
Shafer A, Zhou C, Gehrig PA, Boggess JF
and Bae-Jump VL: Rapamycin potentiates the effects of paclitaxel in
endometrial cancer cells through inhibition of cell proliferation
and induction of apoptosis. Int J Cancer. 126:1144–1154.
2010.PubMed/NCBI
|
|
23
|
Bae-Jump VL, Zhou C, Boggess JF and Gehrig
PA: Synergistic effect of rapamycin and cisplatin in endometrial
cancer cells. Cancer. 115:3887–3896. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kondo Y and Kondo S: Autophagy and cancer
therapy. Autophagy. 2:85–90. 2006. View Article : Google Scholar
|
